OTC •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization40.96 mln
Float53.00 mln
Earnings Date08/28/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
65
/ 100
Outperforming
Debt / Equity
-0.70
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Arch Biopartners is a Toronto-based Canadian company working to bring new medicines to patients with serious kidney conditions. Its most advanced treatment, LSALT Peptide, is currently being tested in Phase 2 clinical trials to address kidney damage caused by inflammation in heart surgery patients. The company is also developing cilastatin to protect kidneys from toxin-related harm, as well as a separate program focused on chronic kidney disease.
